Experimental Serotonergic Agents for the Treatment of Schizophrenia.
cognitive deficits
experimental agents
negative symptoms
schizophrenia
serotonin
Journal
Journal of experimental pharmacology
ISSN: 1179-1454
Titre abrégé: J Exp Pharmacol
Pays: New Zealand
ID NLM: 101530345
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
11
2020
accepted:
16
01
2021
entrez:
12
2
2021
pubmed:
13
2
2021
medline:
13
2
2021
Statut:
epublish
Résumé
Schizophrenia remains one of the most chronic and highly disabling mental disorder. To date, the pathomechanism of schizophrenia is not fully understood and current treatments are characterized by some limitations. First- and second-generation antipsychotics have shown clinical efficacy in treating positive symptoms, while are poorly effective on both negative symptoms and cognitive deficits. Moreover, they can involve many metabolic and neurological side effects, leading to low therapeutic compliance. Many evidence suggested that serotonin may play a complex role in the neurobiology of schizophrenia. Therefore, new drugs targeting 5-HT receptors (5-HTRs) have become an important area of research in schizophrenia in the hope that treatment efficacy may be improved without inducing side effects observed with currently available antipsychotics. Research using the main database sources was conducted to obtain an overview of preclinical and clinical pharmacological 5-HTR-targeted therapies in patients with schizophrenia. We identified 17 experimental serotonergic agents, under study for their potential use in schizophrenia treatment. Particularly, AVN-211, LuAF-35700 and Brilaroxazine are currently under clinical development. Moreover, some compounds showed some pro-cognitive and antipsychotic-like properties in animal models, while other agents showed contradictory effects in improving symptoms and were removed from the development program. Although some serotonergic drugs seem promising for improving the treatment of schizophrenia, further studies regarding the pathophysiological mechanisms of schizophrenia and novel compounds as well as high-quality trials are necessary in order to improve schizophrenia outcomes.
Identifiants
pubmed: 33574716
doi: 10.2147/JEP.S259317
pii: 259317
pmc: PMC7872893
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
49-67Informations de copyright
© 2021 Capuzzi et al.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare for this work.
Références
Behav Brain Res. 2013 Jan 15;237:86-95
pubmed: 23000351
CNS Spectr. 2019 Feb;24(1):88-93
pubmed: 30683165
Expert Opin Drug Discov. 2007 Jun;2(6):799-808
pubmed: 23488998
Curr Med Chem. 2014;21(4):437-57
pubmed: 24164194
BMJ. 2007 Jul 14;335(7610):91-5
pubmed: 17626963
Br J Pharmacol. 2012 Sep;167(2):436-49
pubmed: 22568655
J Pharmacol Sci. 2015 Mar;127(3):362-9
pubmed: 25837935
Neuropharmacology. 2008 Nov;55(6):1056-65
pubmed: 18621404
Acta Psychiatr Scand. 2018 Mar;137(3):187-205
pubmed: 29431197
J Psychopharmacol. 1993 Jan;7(1 Suppl):63-71
pubmed: 22290372
Neuropsychiatr Dis Treat. 2015 Mar 16;11:701-13
pubmed: 25834445
Eur J Med Chem. 2013 Aug;66:122-34
pubmed: 23792350
Eur Arch Psychiatry Clin Neurosci. 2018 Oct;268(7):625-639
pubmed: 29368205
Drugs. 2020 Mar;80(4):417-423
pubmed: 32060882
Dialogues Clin Neurosci. 2011;13(2):155-72
pubmed: 21842613
Lancet. 2009 Jan 3;373(9657):31-41
pubmed: 19058842
Br J Psychiatry. 2017 Oct;211(4):198-204
pubmed: 28882827
Drugs Aging. 2008;25(8):631-47
pubmed: 18665657
Neuropsychopharmacology. 1996 Nov;15(5):442-55
pubmed: 8914117
Mol Pharmacol. 1985 Jun;27(6):600-11
pubmed: 2860558
Br J Pharmacol. 2000 Jul;130(6):1348-52
pubmed: 10903975
J Clin Psychiatry. 2007 Apr;68(4):604-10
pubmed: 17474817
Expert Rev Neurother. 2016 Jun;16(6):601-14
pubmed: 27042868
Behav Brain Res. 2013 Sep 1;252:246-51
pubmed: 23735322
Eur Psychiatry. 2007 Jul;22(5):267-75
pubmed: 17419008
Schizophr Res. 2018 Mar;193:443-444
pubmed: 28641887
Psychopharmacology (Berl). 2006 Dec;189(2):155-64
pubmed: 16953380
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1159-72
pubmed: 14642974
Mol Pharm. 2016 Mar 7;13(3):945-63
pubmed: 26886442
Neuropsychopharmacology. 2017 Oct;42(11):2163-2177
pubmed: 28294132
CPT Pharmacometrics Syst Pharmacol. 2014 Apr 23;3:e111
pubmed: 24759548
Pharmacol Biochem Behav. 2005 Jul;81(3):664-72
pubmed: 15955549
Eur J Pharmacol. 2007 Nov 28;574(2-3):103-11
pubmed: 17692841
Acta Psychiatr Scand. 2015 Mar;131(3):185-96
pubmed: 25597383
Hum Psychopharmacol. 2016 Jul;31(4):325-31
pubmed: 27297936
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
J Nucl Med. 2011 Apr;52(4):526-34
pubmed: 21421726
Psychopharmacology (Berl). 2003 May;167(3):304-14
pubmed: 12677356
CNS Spectr. 2014 Aug;19(4):316-23
pubmed: 23768250
Schizophr Res. 2011 Mar;126(1-3):184-91
pubmed: 21093220
Ther Clin Risk Manag. 2017 Jun 29;13:757-777
pubmed: 28721057
Eur Neuropsychopharmacol. 2014 Oct;24(10):1698-708
pubmed: 25108314
Curr Pharm Des. 2015;21(26):3732-8
pubmed: 26044975
CNS Drugs. 2013 Nov;27(11):879-911
pubmed: 24062193
Curr Pharm Des. 2015;21(26):3739-59
pubmed: 26044973
Schizophr Res. 2017 Nov;189:126-133
pubmed: 28215471
Clin Transl Sci. 2018 Jul;11(4):387-396
pubmed: 29637739
EXCLI J. 2014 Oct 13;13:1163-91
pubmed: 26417330
Neuropharmacology. 2006 Sep;51(3):566-77
pubmed: 16846620
Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33
pubmed: 20569520
Neuropharmacology. 2005 Dec;49(7):996-1006
pubmed: 16009387
J Psychopharmacol. 2019 Nov;33(11):1447-1455
pubmed: 31452444